Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CD95 suppresses immune infiltration in a model of triple negative breast cancer

ABSTRACT: CD95 acts as an immune suppressor for TNBC tumors when grown in syngeneic mice. 4T1 cells were grown in two mouse strains. Comparisons included parental, a pool stably expressing vCas9 and two clones in which CD95/Fas was deleted using CRISPR-Cas9 gene editing, clone #54 and clone #69.

ORGANISM(S): Mus musculus

PROVIDER: GSE154682 | GEO | 2020/07/20

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

RNA-seq after CD95 gene knockout in 4T1 cells

Project description:We examine the differential RNA expression after knocking out CD95/Fas gene in 4T1 cells

2020-07-19 | GSE154676 | GEO

Loss of Fas (CD95) expression by dendritic cells protects from a chronic viral infection

Project description:Chronic viral infections incapacitate adaptive immune responses by 'exhausting' virus-specific T cells, inducing their deletion and reducing productive T cell memory. Viral infection rapidly induces death receptor Fas (CD95) expression by dendritic cells (DCs) making them susceptible to elimination by the immune response. Lymphocytic Choriomeningitis Virus (LCMV) Clone 13, which normally establishes a chronic infection, is rapidly cleared in C57Black/J mice with conditional deletion of Fas in DCs. The immune response to LCMV is characterized by an extended survival of virus-specific effector T cells. Moreover, transfer of Fas-negative DCs from non-infected mice to already-infected animals results in either complete clearance of the virus or a significant reduction of viral titers. Thus, DC-specific Fas expression plays a role in regulation of anti-viral responses and suggests a strategy for stimulation of T cells in chronically infected animals and humans in order to achieve the clearance of persistent viruses. We compared gene expression between splenic DCs from B6.FasKI and B6.CD11c-Cre.FasKI mice. DCs were isolated on day 5 after LCMV infection with 3 mice in each group, for a total of 6 samples. Spleens were collagenase-DNAse digested and sorted by flow to isolate DCs.

2014-05-09 | E-GEOD-57443 | biostudies-arrayexpress

Loss of Fas (CD95) expression by dendritic cells protects from a chronic viral infection

2014-05-09 | GSE57443 | GEO

CD95/Fas ligand mRNA is toxic to cells

Project description:CD95/Fas ligand mRNA is toxic to cells

| PRJNA403815 | ENA

RNA-seq after CD95 gene knockout in 4T1 cells

Project description:RNA-seq after CD95 gene knockout in 4T1 cells

| PRJNA647117 | ENA

CD95/Fas suppresses NF-B activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism

Project description:CD95 expression is preserved in triple-negative breast cancers (TNBCs) and CD95 loss in these cells triggers the induction of a pro-inflammatory program promoting the recruitment of cytotoxic NK cells impairing tumor growth. Herein, we identify a novel interaction partner of CD95, Kip1 ubiquitination-promoting complex protein 2 (KPC2) using an unbiased proteomic approach. Independently of CD95L, CD95/KPC2 interaction contributes to the partial degradation of p105 (NFκB1) and the subsequent generation of p50 homodimers, which transcriptionally represses NF-κB-driven gene expression. Mechanistically, KPC2 interacts with the C-terminal region of CD95 and serves as an adaptor to recruit RelA (p65) and KPC1, which acts as E3 ubiquitin-protein ligase promoting the degradation of p105 into p50. Loss of CD95 in TNBC cells releases KPC2, limiting the formation of the NF-κB inhibitory homodimer complex (p50/p50), promoting NF-κB activation and the production of pro-inflammatory cytokines, that could account for the immune landscape remodeling in TNBC cells

2021-12-06 | PXD027196 | Pride

Transcriptome profile of liver tissue in CD95 activating antibody-treated mice

Project description:In order to identify the effects of CD95 activating antibody on the transcriptome of liver tissue, we performed RNAseq experiments Transcriptome analysis of the liver of mice trated with CD95 activating antibody, compared with liver of mice trated with saline.

2018-11-21 | GSE101822 | GEO

Gene array data for Fas knock-out human cancer cell line and mouse liver tissue

Project description:CD95 (also called FAS and APO-1) is a prototypical death receptor that regulates tissue homeostasis mainly in the immune system through induction of apoptosis. During cancer progression CD95 is frequently downregulated or cells are rendered apoptosis resistant raising the possibility that loss of CD95 is part of a mechanism for tumour evasion. However, complete loss of CD95 is rarely seen in human cancers and many cancer cells express large quantities of CD95 and are highly sensitive to CD95 mediated apoptosis in vitro. Furthermore, cancer patients frequently have elevated levels of the physiological ligand for CD95, CD95L. These data raise the intriguing possibility that CD95 could actually promote the growth of tumours through its nonapoptotic activities. Here we show that cancer cells in general, regardless of their CD95 apoptosis sensitivity, depend on constitutive activity of CD95, stimulated by cancer-produced CD95L, for optimal growth. Consistently, loss of CD95 in mouse models of ovarian cancer and liver cancer reduces cancer incidence as well as the size of the tumours. The tumorigenic activity of CD95 is mediated by a pathway involving JNK and c-Jun. These results demonstrate that CD95 plays a major growth promoting role during tumorigenesis and suggest that efforts to inhibit its activity rather than to enhance its activation should be considered during cancer therapy. There are 3 arrays for human ovarian cancer cell line, 2 arrays for human liver cancer cell line, and 2 arrays for mouse liver tissue. All the arrays are paired arrays with or without Fas knock-out.

2010-04-02 | E-GEOD-21154 | biostudies-arrayexpress

CD95 suppresses immune infiltration in a model of triple negative breast cancer

Project description:CD95 suppresses immune infiltration in a model of triple negative breast cancer

| PRJNA647186 | ENA

CD95/Fas increases stemness in cancer cells by inducing a STAT1 dependent Type I interferon response

Project description:CD95/Fas increases stemness in cancer cells by inducing a STAT1 dependent Type I interferon response

| PRJNA322761 | ENA